![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Nevirapine hemihydrate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2013-079 - Rev 00
This Chemical Type CEP, issued on September 10, 2018, remains in force until May 13, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 2479 associated with this CEP further emphasizes